NRXPNRx Pharmaceuticals, Inc.

Moby summary of NRx Pharmaceuticals, Inc.'s Q2 2026 earnings call

NRX Pharmaceuticals reports improved net loss, strong cash position, and key regulatory progress for its ketamine and CNS pipeline.

Key Takeaways; Cannabis Sector Curaleaf Holdings Announced Intention to Launch a Hostile Takeover Bid to Acquire Aurora Cannabis Organigram Posted Record Quarter as Sanity Group Acquisition Fueled Global Expansion Key Takeaways; Psychedelic Sector Optimi Health Set Up US$100 Million Equity Facility to Support Growth Definium Therapeutics’ Phase 3 Trial Delivered Strong Results for DT120 in […]

NRx Pharmaceuticals (NRXP) delivered earnings and revenue surprises of -100.00% and -54.13%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

NRx Pharmaceuticals (NASDAQ:NRXP) said it has completed the first-cycle U.S. Food and Drug Administration review of its abbreviated new drug application, or ANDA, for preservative-free ketamine, with one remaining issue related to the product’s vial connector. Jonathan Javitt, the company’s founder

We recently compiled a list of the 7 Best Psychedelic Stocks to Buy According to Analysts. NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) is one of the best psychedelic stocks on our list. TheFly reported on June 25 that NRXP issued a statement responding to claims made by Kadima Neuropsychiatry Institute regarding the failed acquisition of Kadima by HOPE […]